BRUGIA, MARCO
BRUGIA, MARCO
Medicina Sperimentale e Clinica
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.
2018 Lavacchi D, Nobili S, Brugia M, Paderi A, Fancelli S, Caliman E, Vergoni F, Mini E.
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience
2021 Lavacchi D.; Roviello G.; Giommoni E.; Dreoni L.; Derio S.; Brugia M.; Amedei A.; Pillozzi S.; Antonuzzo L.
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer.
2018 Bartolini I, Ringressi MN, Melli F, Risaliti M, Brugia M, Mini E, Batignani G, Bechi P, Boni L, Taddei A.
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis
2021 Paderi A.; Gambale E.; Botteri C.; Giorgione R.; Lavacchi D.; Brugia M.; Mazzoni F.; Giommoni E.; Bormioli S.; Amedei A.; Pillozzi S.; Cerinic M.M.; Antonuzzo L.
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS
2025 Massaro G, Venturini J, Rossini D, Vannini A, Brugia M, Lavacchi D, Conticello C, Valle I, Ravizza D, Pillozzi S, Antonuzzo L.
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives
2021 Fancelli S.; Caliman E.; Mazzoni F.; Brugia M.; Castiglione F.; Voltolini L.; Pillozzi S.; Antonuzzo L.
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
2021 Salvianti, Francesca; Gelmini, Stefania; Mancini, Irene; Pazzagli, Mario; Pillozzi, Serena; Giommoni, Elisa; Brugia, Marco; Di Costanzo, Francesco; Galardi, Francesca; De Luca, Francesca; Castiglione, Francesca; Messerini, Luca; Pinzani, Pamela; Antonuzzo, Lorenzo
Current status and future perspectives in HER2 positive advanced gastric cancer
2022 Roviello, G; Catalano, M; Iannone, L F; Marano, L; Brugia, M; Rossi, G; Aprile, G; Antonuzzo, L
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Tassi, R.; Mini, E.; D'Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Napoli, C.; Picariello, L.; Brugia, M.; Landini, I.; Mazzei, T.; Tonelli, F.; Nobili, S.
Emerging drugs in refractory colorectal cancer
2015 Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
2021 Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A.
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
2023 Lavacchi, Daniele; Roviello, Giandomenico; Guidolin, Alessia; Romano, Silvia; Venturini, Jacopo; Caliman, Enrico; Vannini, Agnese; Giommoni, Elisa; Pellegrini, Elisa; Brugia, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors.
2015 Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
2016 Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift
2025 Massaro G, Paulet A, Lavacchi D, Brugia M, Rossini D, Giommoni E, Catalano M, Pillozzi S, Antonuzzo L, Roviello G.
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations"
2020 Caliman, Enrico; Petreni, Paolo; Brugia, Marco; Antonuzzo, Lorenzo; Mazzoni, Francesca
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer
2023 Cosso, Federica; Lavacchi, Daniele; Fancelli, Sara; Caliman, Enrico; Brugia, Marco; Rossi, Gemma; Winchler, Costanza; Pillozzi, Serena; Antonuzzo, Lorenzo
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
2022 Lavacchi, Daniele; Fancelli, Sara; Roviello, Giandomenico; Castiglione, Francesca; Caliman, Enrico; Rossi, Gemma; Venturini, Jacopo; Pellegrini, Elisa; Brugia, Marco; Vannini, Agnese; Bartoli, Caterina; Cianchi, Fabio; Pillozzi, Serena; Antonuzzo, Lorenzo
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect
2017 Antonuzzo, Lorenzo; Lunghi, Alice; Petreni, Paolo; Brugia, Marco; Laffi, Alice; Giommoni, Elisa; Mela, Marinella M; Mazzoni, Francesca; Balestri, Vanni; Costanzo, Francesco Di
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. | 2018 | Lavacchi D, Nobili S, Brugia M, Paderi A, Fancelli S, Caliman E, Vergoni F, Mini E. | |
| A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S | |
| Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience | 2021 | Lavacchi D.; Roviello G.; Giommoni E.; Dreoni L.; Derio S.; Brugia M.; Amedei A.; Pillozzi S.; Antonuzzo L. | |
| Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. | 2018 | Bartolini I, Ringressi MN, Melli F, Risaliti M, Brugia M, Mini E, Batignani G, Bechi P, Boni L, Taddei A. | |
| Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis | 2021 | Paderi A.; Gambale E.; Botteri C.; Giorgione R.; Lavacchi D.; Brugia M.; Mazzoni F.; Giommoni E.; Bormioli S.; Amedei A.; Pillozzi S.; Cerinic M.M.; Antonuzzo L. | |
| Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS | 2025 | Massaro G, Venturini J, Rossini D, Vannini A, Brugia M, Lavacchi D, Conticello C, Valle I, Ravizza D, Pillozzi S, Antonuzzo L. | |
| Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives | 2021 | Fancelli S.; Caliman E.; Mazzoni F.; Brugia M.; Castiglione F.; Voltolini L.; Pillozzi S.; Antonuzzo L. | |
| Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study | 2021 | Salvianti, Francesca; Gelmini, Stefania; Mancini, Irene; Pazzagli, Mario; Pillozzi, Serena; Giommoni, Elisa; Brugia, Marco; Di Costanzo, Francesco; Galardi, Francesca; De Luca, Francesca; Castiglione, Francesca; Messerini, Luca; Pinzani, Pamela; Antonuzzo, Lorenzo | |
| Current status and future perspectives in HER2 positive advanced gastric cancer | 2022 | Roviello, G; Catalano, M; Iannone, L F; Marano, L; Brugia, M; Rossi, G; Aprile, G; Antonuzzo, L | |
| D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Tassi, R.; Mini, E.; D'Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Napoli, C.; Picariello, L.; Brugia, M.; Landini, I.; Mazzei, T.; Tonelli, F.; Nobili, S. | |
| Emerging drugs in refractory colorectal cancer | 2015 | Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E | |
| Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy | 2021 | Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A. | |
| Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer | 2023 | Lavacchi, Daniele; Roviello, Giandomenico; Guidolin, Alessia; Romano, Silvia; Venturini, Jacopo; Caliman, Enrico; Vannini, Agnese; Giommoni, Elisa; Pellegrini, Elisa; Brugia, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. | 2015 | Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S | |
| Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy | 2016 | Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S | |
| Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift | 2025 | Massaro G, Paulet A, Lavacchi D, Brugia M, Rossini D, Giommoni E, Catalano M, Pillozzi S, Antonuzzo L, Roviello G. | |
| In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" | 2020 | Caliman, Enrico; Petreni, Paolo; Brugia, Marco; Antonuzzo, Lorenzo; Mazzoni, Francesca | |
| Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer | 2023 | Cosso, Federica; Lavacchi, Daniele; Fancelli, Sara; Caliman, Enrico; Brugia, Marco; Rossi, Gemma; Winchler, Costanza; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer | 2022 | Lavacchi, Daniele; Fancelli, Sara; Roviello, Giandomenico; Castiglione, Francesca; Caliman, Enrico; Rossi, Gemma; Venturini, Jacopo; Pellegrini, Elisa; Brugia, Marco; Vannini, Agnese; Bartoli, Caterina; Cianchi, Fabio; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect | 2017 | Antonuzzo, Lorenzo; Lunghi, Alice; Petreni, Paolo; Brugia, Marco; Laffi, Alice; Giommoni, Elisa; Mela, Marinella M; Mazzoni, Francesca; Balestri, Vanni; Costanzo, Francesco Di |